Spravato 28 mg Nasal Solution (Spray) الفلبين - الإنجليزية - FDA (Food And Drug Administration)

spravato 28 mg nasal solution (spray)

janssen pharmaceuticals, inc.; importer: johnson & johnson (philippines), inc. - esketamine (as hydrochloride) - nasal solution (spray) - 28 mg

SPRAVATO SOLUCIÓN PARA PULVERIZACIÓN NASAL 28 mg (ESKETAMINA) شيلي - الإسبانية - ISPC (Instituto de Salud Pública de Chile)

spravato solución para pulverización nasal 28 mg (esketamina)

johnson & johnson de chile s.a. - esketamina - esketamina clorhidrato 37,100 mg - spravato está indicado, en combinación con un antidepresivo oral, para el tratamiento de depresión resistente al tratamiento (drt) en adultos

SYNDROS- dronabinol solution الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

syndros- dronabinol solution

insys therapeutics, inc. - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol 5 mg in 1 ml - syndros is indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. syndros is contraindicated in patients: - with a history of a hypersensitivity reaction to dronabinol. reported hypersensitivity reactions to dronabinol include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing, throat tightness [see adverse reactions (6.2)] . - with a history of a hypersensitivity reaction to alcohol. - who are receiving, or have recently received, disulfiram- or metronidazole-containing products within 14 days [see warning and precautions (5.3)] . syndros contains 50% (w/w) dehydrated alcohol and 5.5% (w/w) propylene glycol. risk summary syndros, a synthetic cannabinoid containing alcohol, may cause fetal harm. avoid use of syndros in pregnant women. although there is l